We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 92.12%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PGNX
26
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$29.7M 0.24%
3,150,808
– –
MRUS
27
DELISTED
Merus
MRUS
$28.3M 0.23%
1,160,014
– –
ACGN
28
DELISTED
Aceragen Inc
ACGN
$25.4M 0.21%
75,712
+105
+0.1% +$25.3K
SGMO
29
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$23.6M 0.19%
4,530,901
+475,025
+12% +$1.91M
LKFT
30
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$22.4M 0.18%
259,894
– –
XNCR icon
31
Xencor
XNCR
$1.45B
$20.9M 0.17%
872,072
– –
HALO icon
32
Halozyme
HALO
$9.88B
$18M 0.15%
1,391,507
– –
NDRM
33
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$15.2M 0.12%
571,667
– –
NTLA icon
34
Intellia Therapeutics
NTLA
$1.51B
$15M 0.12%
1,062,120
– –
SAGE
35
DELISTED
Sage Therapeutics
SAGE
$14.8M 0.12%
208,328
– –
AIMT
36
DELISTED
Aimmune Therapeutics
AIMT
$14.6M 0.12%
673,908
– –
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$14.2M 0.12%
1,585,913
-1,000,000
-39% -$10.6M
DERM
38
DELISTED
Dermira, Inc.
DERM
$14.2M 0.12%
415,448
+89,020
+27% +$2.87M
AERI
39
DELISTED
Aerie Pharmaceuticals
AERI
$13.6M 0.11%
299,356
– –
FOMX
40
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$12.2M 0.1%
2,466,702
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.8M 0.1%
2,269,198
– –
IMGN
42
DELISTED
Immunogen Inc
IMGN
$11.7M 0.1%
3,015,353
– –
LJPC
43
DELISTED
La Jolla Pharmaceutical Company
LJPC
$11.3M 0.09%
379,134
+365,388
+2,658% +$9.33M
CPRX
44
DELISTED
Catalyst Pharmaceutical
CPRX
$9.95M 0.08%
5,102,153
– –
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.9M 0.08%
609,166
– –
ALKS icon
46
Alkermes
ALKS
$8.11B
$8.79M 0.07%
150,251
– –
ABEO icon
47
Abeona Therapeutics
ABEO
$355M
$8.42M 0.07%
67,375
– –
RIGL icon
48
Rigel Pharmaceuticals
RIGL
$723M
$8.34M 0.07%
251,888
+50,000
+25% +$1.27M
ACHN
49
DELISTED
Achillion Pharmaceuticals
ACHN
$7.82M 0.06%
1,856,637
– –
LGND icon
50
Ligand Pharmaceuticals
LGND
$5.77B
$7.77M 0.06%
117,638
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Baker Bros. Advisors held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Baker Bros. Advisors's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Baker Bros. Advisors added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Baker Bros. Advisors's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Baker Bros. Advisors fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Baker Bros. Advisors opened 4 new positions and closed 18 in Q1 2017.
  • Baker Bros. Advisors's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.